Key takeaways
- Retatrutide is Eli Lilly’s investigational peptide that activates the GIP, GLP-1 and glucagon receptors; cagrilintide is Novo Nordisk’s investigational long-acting analogue of amylin, a hormone made by the pancreas.
- The published retatrutide trials we found gave it alone. Most of cagrilintide’s phase 3 data come from CagriSema, its combination with semaglutide, the active ingredient of the prescription medicines Ozempic and Wegovy.
- We found no trial comparing the two; the one study we found that gave both used them together, in rats (PubMed and ClinicalTrials.gov, 18 Nov 2026).
- FDA says both “cannot be used in compounding under federal law” and have “not been found safe and effective for any condition”.
- Lilly plans to seek US approval of retatrutide in the first quarter of 2027; Novo Nordisk filed for CagriSema in December 2025 and expects an FDA decision in the fourth quarter of 2026.
01What is retatrutide?
Retatrutide, development code LY3437943, is a single peptide that activates the receptors for three hormones: GIP, GLP-1 and glucagon. A 2026 review in Pharmaceutics describes it as a 39-amino-acid peptide built on a GIP-based sequence, with a fatty acid attached (lipidated). Eli Lilly developed it and funded each of its clinical trials cited here.
The published trials we cite gave it as a single drug, not in a combination product, to adults with obesity or overweight, some with type 2 diabetes. It is investigational: the TGA wrote on 5 November 2026 that it “has not been approved by the TGA or any comparable international regulator”. The full profile: what is retatrutide?
02What is cagrilintide?
Cagrilintide is a long-acting analogue of amylin, a hormone made by the pancreas. Novo Nordisk scientists described its development in 2021 as a “stable, lipidated long-acting amylin analogue”, and the design paper of the REDEFINE 3 trial calls it an amylin receptor agonist.
Most of its late-stage testing is as CagriSema, a fixed combination with semaglutide. Semaglutide is a GLP-1 receptor agonist and the active ingredient of the prescription medicines Ozempic and Wegovy. REDEFINE 1 also had a smaller group given cagrilintide alone, and Novo Nordisk has registered phase 3 trials of cagrilintide on its own, none of which has posted results (ClinicalTrials.gov, 18 Nov 2026). The full profile: what is cagrilintide?
03How do retatrutide and cagrilintide differ?
The same questions for both, checked on 18 November 2026.
| Question | Retatrutide | Cagrilintide |
|---|---|---|
| What it is | A single peptide that activates three hormone receptors | A long-acting analogue of amylin, a hormone made by the pancreas |
| Receptors | GIP, GLP-1 and glucagon receptors | Amylin receptors; the REDEFINE 3 design paper calls it an amylin receptor agonist |
| Structure | 39 amino acids on a GIP-based sequence, lipidated (2026 review) | A lipidated amylin analogue (Novo Nordisk scientists, 2021) |
| Developer, who funded the trials | Eli Lilly | Novo Nordisk |
| How it has been tested | On its own, in every published trial we list | Mostly with semaglutide, as CagriSema; alone in a 2021 phase 2 trial and in single-drug arms of some phase 3 trials, such as REDEFINE 1 |
| Phase 3 records on ClinicalTrials.gov, 18 Nov 2026 | 14, all sponsored by Lilly: 5 completed, 9 active or recruiting | 23, all sponsored by Novo Nordisk: 10 completed, 13 active, recruiting, not yet recruiting or withdrawn |
| Phase 3 programme in overweight and obesity | TRIUMPH (retatrutide alone) | REDEFINE (CagriSema) |
| Longest published phase 3 trials | 80 weeks: TRIUMPH-1 and TRIUMPH-2, published 29 Sep 2026 | 68 weeks, among them REDEFINE 1 and REDEFINE 2, online 22 Jun 2025 |
| Heart-outcomes trial | TRIUMPH-Outcomes, about 10,000 adults; primary completion expected Feb 2029 (NCT06383390) | REDEFINE 3, 7,076 adults; primary completion expected Sep 2027 (NCT05669755) |
| Evidence tier | T1, investigational: randomised trials of Lilly’s product | T1, investigational: randomised trials of Novo Nordisk’s product, mostly in combination |
| United States | Not approved. Lilly plans to submit an application in the first quarter of 2027 | Not approved. Novo Nordisk filed for CagriSema in Dec 2025 and expects a decision in the fourth quarter of 2026 |
| European Union | No EU-wide authorisation: no medicine containing it in EMA’s data (18 Nov 2026) | No EU-wide authorisation: no medicine containing it in EMA’s data (18 Nov 2026) |
| FDA on compounding | “cannot be used in compounding under federal law” | “cannot be used in compounding under federal law” |
| WADA Prohibited List | Not named on the 2026 or 2027 List; WADA’s 2027 notes say an unnamed peptide “may still be prohibited” | Not named on the 2026 or 2027 List; WADA’s 2027 notes say an unnamed peptide “may still be prohibited” |
| Regulator actions on products sold online | FDA warning letters (Dec 2024 to Aug 2026); MHRA (Oct 2025, Oct 2026); TGA (Sep 2026, Nov 2026) | FDA warning letters (Dec 2024, Mar 2026); no MHRA release names it (GOV.UK search, 18 Nov 2026) |
How to read the table. The two drugs were not tested the same way. Retatrutide’s phase 3 data are for retatrutide alone; most of cagrilintide’s phase 3 data are for cagrilintide combined with semaglutide. Their trials also differ in length, population and comparison, so their results cannot be lined up as if they described the same thing. We give no efficacy figures for either: neither is approved, and we do not repeat efficacy figures for investigational drugs. How we grade evidence: evidence grades.
04Has any research compared retatrutide and cagrilintide?
We found no trial that compares them. On 18 November 2026, ClinicalTrials.gov returned no study with both as interventions, and PubMed returned 22 records naming both in the title or abstract.
One animal study gave them together. A 2026 study from the University of Copenhagen gave retatrutide and cagrilintide together to diet-induced obese male rats, against each one alone and against other drug combinations. It tested them as a pair, not as alternatives, in rats (T3), and it tells us nothing about people.
The other 21 records discuss them among other drugs. They are reviews, systematic reviews and network meta-analyses. A network meta-analysis, such as a 2026 BMJ review of 262 trials of 19 drugs, compares drugs indirectly, across different trials with different populations and durations. That is not head-to-head evidence. We do not reproduce their rankings or estimates.
05How do regulators treat retatrutide and cagrilintide?
Neither is an approved medicine in the US or the EU as of 18 November 2026. FDA names them in the same sentence.
FDA. FDA’s page on unapproved GLP-1 drugs (content current 1 October 2026) says: “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.” Drugs@FDA lists no application for either (openFDA search, 18 November 2026).
Where each stands with FDA. Lilly said on 29 September 2026 that it “plans to submit a Biologics License Application (BLA) in Q1 2027” for retatrutide. Novo Nordisk filed a New Drug Application for CagriSema in December 2025, and on 20 October 2026 it said that “A decision is expected in Q4 2026”, that “CagriSema is not approved for use in the United States” and that “Safety and efficacy are not established.” A filing asks FDA to review the evidence; it is not an approval. US drug law and peptides: are peptides legal in the US?
Products sold online. On 10 December 2024 FDA wrote to an online seller that its “Retatrutide” and “Cagrilintide” products, listed alongside semaglutide, tirzepatide and mazdutide products, were unapproved new drugs, despite labels reading “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY”. Later letters named retatrutide (four sellers, 24 August 2026) and cagrilintide (another seller, 31 March 2026). For retatrutide, two more regulators have acted. The MHRA said on 15 October 2026 that “Retatrutide has not been authorised for use in the UK.” The TGA wrote on 5 November 2026 that tested products from one brand “contained less retatrutide than stated on the label, with significant variation between samples”. A GOV.UK search on 18 November 2026 found no MHRA release that names cagrilintide.
A lab report can show what one tested sample contained. It cannot turn that sample into the product either company tested, or into an approved medicine. What a research-use label does and does not mean: research use only, explained. Documented cases: contamination and mislabeling.
06What we don’t know about retatrutide and cagrilintide
- How they would compare in people. No trial has tested one against the other, and their trials were built differently: retatrutide alone, cagrilintide mostly with semaglutide.
- Whether FDA will approve either, and when. Novo Nordisk expects a decision on CagriSema in the fourth quarter of 2026; Lilly plans its retatrutide filing for the first quarter of 2027.
- What the heart-outcomes trials will show. TRIUMPH-Outcomes and REDEFINE 3 are listed as active, not recruiting.
- What the phase 3 trials of cagrilintide on its own will report. None has posted results (ClinicalTrials.gov, 18 Nov 2026).
- What any vial sold online under either name contains. A lab report shows only what the tested sample held.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.